Abstract：Objective：To observe the curative effect of the therapy of Zhiling Capsules combined with Tacrolimus Capsules on membranous nephropathy(MN) and its effect on anti- M type phospholipase A2 receptor(PLA2R) antibody. Methods： A total of 98 patients with MN were selected and divided into the control group and the observation group according to the random number table method，with 49 cases in each group. The control group was given Tacrolimus Capsules，and the observation group was additionally given oral administration of Zhiling Capsules based on the treatment of the control group. Both groups were treated for four weeks continuously. The clinical effects and incidence of adverse reactions were compared between the two groups. Before and after treatment，the changes of levels of kidney function，including plasma albumin(Alb) ， serum creatinine(SCr) ， microalbuminuria(MAU) ， blood urea nitrogen(BUN) and 24- hour urine protein(24 hUP)， blood lipid， including total cholesterol(TC)， triglyceride(TG) and lowdensity lipoprotein cholesterol(LDL-C)，and anti-PLA2R antibody were compared between the two groups. Results： The total clinical effective rate was 93.88% in the control group， and was 79.59% in the observation group， the difference being significant(P＜0.05). After treatment， the levels of SCr， MAU， BUN and 24 hUP in the two groups were decreased when compared with those before treatment，and the levels of Alb were increased，differences being significant(P＜0.05)；the levels of SCr，MAU，BUN and 24 hUP in the observation group were lower and the level of Alb in the observation group was higher than those in the control group，differences being significant(P＜0.05). After treatment，the levels of TC，TG and LDL-C in the two groups were decreased when compared with those before treatment，and the above three levels in the observation group were lower than those in the control group， differences being significant(P＜0.05). After treatment，the levels of anti-PLA2R antibody in the two groups were decreased when compared with those before treatment(P＜0.05)，and the above level in the observation group was lower than that in the control group(P＜0.05). The incidence of adverse reactions was 14.29% in the control group and 4.08% in the observation group， the difference being significant(P＜0.05). Conclusion： The therapy of Zhiling Capsules combined with Tacrolimus Capsules for MN can effectively enhance the clinical effect，improve the kidney function，and reduce the levels of blood lipid and anti-PLA2R antibody， with high medication safety.